Home
/
Kiniksa Pharmaceuticals International, plc
/
Financials
/
Quarterly
Kiniksa Pharmaceuticals International, plc — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Kiniksa Pharmaceuticals International, plc filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$180.86M
Oct 28, 2025
Q3
2025
Sep 30, 2024
$112.21M
Oct 28, 2025
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$180.86M
Oct 28, 2025
Q2
2025
Jun 30, 2025
$156.80M
Jul 29, 2025
Q1
2025
Mar 31, 2025
$137.79M
Apr 29, 2025
Q3
2025
Sep 30, 2024
$112.21M
Oct 28, 2025
Q2
2025
Jun 30, 2024
$108.63M
Jul 29, 2025
Q1
2025
Mar 31, 2024
$79.86M
Apr 29, 2025
Q3
2024
Sep 30, 2023
$67.05M
Oct 29, 2024
Q2
2024
Jun 30, 2023
$71.47M
Jul 25, 2024
Q1
2024
Mar 31, 2023
$48.35M
Apr 25, 2024
Q3
2023
Sep 30, 2022
$99.14M
Nov 2, 2023
Q2
2023
Jun 30, 2022
$26.97M
Aug 1, 2023
Q1
2023
Mar 31, 2022
$32.19M
May 4, 2023
Q3
2022
Sep 30, 2021
$12.10M
Nov 3, 2022
Q2
2022
Jun 30, 2021
$7.70M
Aug 4, 2022
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$18.44M
Oct 28, 2025
Q2
2025
Jun 30, 2025
$17.83M
Jul 29, 2025
Q3
2025
Jun 30, 2025
$17.83M
Oct 28, 2025
Q2
2025
Mar 31, 2025
$8.54M
Jul 29, 2025
Q3
2025
Mar 31, 2025
$8.54M
Oct 28, 2025
Q1
2025
Mar 31, 2025
$8.54M
Apr 29, 2025
Q3
2025
Sep 30, 2024
($12.69M)
Oct 28, 2025
Q3
2025
Jun 30, 2024
($3.91M)
Oct 28, 2025
Q2
2025
Jun 30, 2024
($3.91M)
Jul 29, 2025
Q1
2025
Mar 31, 2024
($17.70M)
Apr 29, 2025
Q2
2025
Mar 31, 2024
($17.70M)
Jul 29, 2025
Q3
2025
Mar 31, 2024
($17.70M)
Oct 28, 2025
Q3
2024
Sep 30, 2023
($13.86M)
Oct 29, 2024
Q2
2024
Jun 30, 2023
$14.97M
Jul 25, 2024
Q3
2024
Jun 30, 2023
$14.97M
Oct 29, 2024
Q3
2024
Mar 31, 2023
($12.27M)
Oct 29, 2024
Q1
2024
Mar 31, 2023
($12.27M)
Apr 25, 2024
Q2
2024
Mar 31, 2023
($12.27M)
Jul 25, 2024
Q3
2023
Sep 30, 2022
$224.09M
Nov 2, 2023
Q3
2023
Jun 30, 2022
($19.98M)
Nov 2, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$24.02M
Oct 28, 2025
Q2
2025
Jun 30, 2025
$20.16M
Jul 29, 2025
Q1
2025
Mar 31, 2025
$13.27M
Apr 29, 2025
Q3
2025
Sep 30, 2024
($9.66M)
Oct 28, 2025
Q2
2025
Jun 30, 2024
($117.0K)
Jul 29, 2025
Q1
2025
Mar 31, 2024
($16.54M)
Apr 29, 2025
Q3
2024
Sep 30, 2023
($10.93M)
Oct 29, 2024
Q2
2024
Jun 30, 2023
($3.15M)
Jul 25, 2024
Q1
2024
Mar 31, 2023
($11.20M)
Apr 25, 2024
Q3
2023
Sep 30, 2022
$46.41M
Nov 2, 2023
Q2
2023
Jun 30, 2022
($19.37M)
Aug 1, 2023
Q1
2023
Mar 31, 2022
($23.32M)
May 4, 2023
Q3
2022
Sep 30, 2021
($30.67M)
Nov 3, 2022
Q2
2022
Jun 30, 2021
($40.56M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($49.28M)
May 5, 2022
Q3
2021
Sep 30, 2020
($43.22M)
Nov 4, 2021
Q2
2021
Jun 30, 2020
($31.86M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($29.39M)
May 6, 2021
Q3
2020
Sep 30, 2019
($30.45M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($39.29M)
Aug 4, 2020